David Katz
Matrix Advisors Value Fund
David Katz Zimmer Biomet Holdings Inc stake
total: 54
Matrix Advisors Value Fund ZBH trades
- Total transactions:
- 14
- New positions:
- 1
- Added:
- 5
- Reduced:
- 8
- Held since:
- 2020 Q1
- Held for:
- 20 quarters
- Latest activity:
- 2024 Q4
According to 2024 Q4 report, David Katz holds 12,600 Zimmer Biomet Holdings Inc (ZBH) shares with a market value of roughly $1.33M accounting for 1.89% of the overall portfolio. To date, the estimated cost basis is nearly $113.91 for "buy" trades and estimated average "sell" price is $127.46. Matrix Advisors Value Fund first purchased ZBH in 2020 Q1, initially acquiring 11,900 shares. Since the initial investment in Zimmer Biomet Holdings Inc (ZBH), Matrix Advisors Value Fund has made 13 more transactions.
When did David Katz buy Zimmer Biomet Holdings Inc (ZBH)?
David Katz first invested in Zimmer Biomet Holdings Inc (ZBH) in 2020 Q1 at the reported quarter-end price of $101.08 per share.
What's the cost basis of Matrix Advisors Value Fund's ZBH stake?
The estimated cost basis for Zimmer Biomet Holdings Inc (ZBH) stake is around $113.91 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $113.91
- Weighted AVG sell price:
- $127.46
David Katz's historical trades in Zimmer Biomet Holdings Inc
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q4
|
1.89%
|
12,600
|
$105.63
|
$1,330,938
|
-23.17% (-3,800)
|
-0.58%
|
|
2023 Q4
|
3.30%
|
16,400
|
$121.70
|
$1,995,880
|
+42.61% (+4,900)
|
+0.99%
|
|
2023 Q3
|
2.41%
|
11,500
|
$112.22
|
$1,290,530
|
-1.71% (-200)
|
-0.04%
|
|
2023 Q2
|
2.99%
|
11,700
|
$145.60
|
$1,703,520
|
-10.00% (-1,300)
|
-0.34%
|
|
2022 Q4
|
3.24%
|
13,000
|
$127.50
|
$1,657,500
|
-21.69% (-3,600)
|
-0.94%
|
|
2022 Q1
|
3.22%
|
16,600
|
$127.90
|
$2,123,140
|
+12.93% (+1,900)
|
+0.37%
|
|
2021 Q4
|
2.65%
|
14,700
|
$127.04
|
$1,867,488
|
+33.03% (+3,650)
|
+0.66%
|
|
2021 Q3
|
2.41%
|
11,050
|
$146.36
|
$1,617,278
|
+11.62% (+1,150)
|
+0.25%
|
|
2021 Q2
|
2.44%
|
9,900
|
$160.82
|
$1,592,118
|
-1.98% (-200)
|
-0.05%
|
|
2021 Q1
|
2.68%
|
10,100
|
$160.08
|
$1,616,808
|
-5.16% (-550)
|
-0.16%
|
|
2020 Q4
|
3.05%
|
$154.09
|
-10.50% (-1,250)
|
|||
|
2020 Q3
|
3.42%
|
$136.14
|
-4.03% (-500)
|
|||
|
2020 Q2
|
3.07%
|
$119.36
|
+4.20% (+500)
|
|||
|
2020 Q1
|
3.04%
|
$101.08
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.